Advertisement
Advertisement
ADPT
Adaptive Biotechnologies Corporation Common Stock
22.57
USDSponsored
-1.61
-6.66%
Jul 31, 15:59 UTC -4
Closed
After-Market
22.57
0.00
-0.02%
ADPT Earnings Reports
Positive Surprise Ratio
ADPT beat 24 of 29 last estimates.
83%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$72.61M
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
+1.48%
/+10.00%
Implied change from Q3 25 (Revenue/ EPS)
-22.73%
/-283.33%
Adaptive Biotechnologies Corporation Common Stock earnings per share and revenue
On Jul 29, 2026, ADPT reported earnings of -0.10 USD per share (EPS) for Q2 26, beating the estimate of -0.13 USD, resulting in a 26.69% surprise. Revenue reached 71.55 million, compared to an expected 67.20 million, with a 6.47% difference. The market reacted with a +7.18% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.11 USD, with revenue projected to reach 72.61 million USD, implying an increase of 10.00% EPS, and increase of 1.48% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alnylam Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.58
Actual
$1.21
Surprise
-23.70%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.00
Surprise
-90.05%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
-$0.21
Surprise
+18.13%
Anavex Life Sciences
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.06
Surprise
+15.97%
Crescent Biopharma, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.74
Surprise
+8.74%
FAQ
What were Adaptive Biotechnologies Corporation Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Adaptive Biotechnologies Corporation Common Stock reported EPS of -$0.10, beating estimates by 26.69%, and revenue of $71.55M, 6.47% above expectations.
How did the market react to Adaptive Biotechnologies Corporation Common Stock's Q2 2026 earnings?
The stock price moved up 7.18%, changed from $22.56 before the earnings release to $24.18 the day after.
When is Adaptive Biotechnologies Corporation Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Adaptive Biotechnologies Corporation Common Stock's next earnings report?
Based on 10
analysts, Adaptive Biotechnologies Corporation Common Stock is expected to report EPS of -$0.11 and revenue of $72.61M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement